ABL Bio

Pioneering bispecific antibodies for oncology and neurodegenerative diseases

Seongnam, South Korea · Founded 2016

Headquarters
Seongnam
Employees
51–200
Founded
2016
Business Model
B2B
Website
ablbio.com

About

ABL Bio is a South Korean research-led biotechnology company and pioneer in bispecific antibodies, with programs spanning immuno-oncology, neurodegenerative diseases, and antibody-drug conjugates. Founded in 2016 by Sang Hoon Lee and listed on the KOSDAQ exchange (298380), the company develops novel therapeutic platforms that address high unmet medical needs by combining bispecific antibody expertise with innovative drug delivery approaches. ABL Bio collaborates with global partners to advance its pipeline — which includes programs such as ABL301 for Parkinson's disease and ABL503 for solid tumors — and in 2025 established NEOK Bio in California with $75 million from Blackstone Life Sciences to advance two bispecific ADCs in the US market.

Summary

ABL Bio is a Biotech company based in Seongnam, South Korea, founded in 2016.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ABL Bio on Indexed.vc
<a href="https://indexed.vc/companies/abl-bio"><img src="https://indexed.vc/api/badge/company/abl-bio" alt="ABL Bio on Indexed.vc" width="260" height="76" /></a>